ALFA Finder| Revenue growth | Consolidated revenue ₹136.3 Cr, +110% YoY on low base; +45% QoQ. |
|---|---|
| Margins | Standalone gross margin 35% vs 44.1% YoY on input costs; expansion lumpy. |
| Order book | Order book ₹117 Cr (corrected from ₹180 Cr slide); ~1.5x Q2 standalone revenue. |
| Demand visibility | Order book ₹117 Cr; standalone H1 revenue flat YoY; H2 must carry growth. |
| Management confidence | Balanced: candid on margin pressure; defers Innoxel guidance revision to Q3. |
Growth
Revenue +110% YoY off a weak base; +45% QoQ. Innoxel +253% on milestones; standalone H1 revenue flat YoY.
Outlook
Maintains FY27 guidance: standalone 10-15% growth, 10-15% margin; Innoxel 35-45% growth, 20-25% margin, under review at Q3.
Risks
Standalone gross margin 35% (from 44.1%) on pre-priced orders; Innoxel revenue lumpy and milestone-driven; H1 Innoxel EBITDA just under 20% band.
Earnings Call Transcript filed with BSE, NSE: BPLPHARMA. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,853.70
- Market cap
- ₹1,278 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- 1027.2×Sector 43.0×
- Promoter holding
- 67.20%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹136.3 Cr (+110.9% YoY), EBITDA ₹23.6 Cr (17.3%), PAT ₹11.8 Cr; Innoxel turned profitable.
Bharat Parenterals Q2 FY27 Results: Turns Profitable, Net Profit ₹11.8 Cr
Bharat Parenterals approved unaudited standalone results for the quarter ended 30 September 2026. The company reported profit and revenue growth versus the prior-year quarter.
- Key figure
- Net profit ₹11.8 Cr
Bharat Parenterals Board Meeting Date
Bharat Parenterals will hold a board meeting on October 29, 2026 to consider unaudited standalone and consolidated results. Trading window has been closed since October 1, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals held an EGM via video conferencing on October 23, 2026. Members considered a preferential equity issue and Section 186 investment and guarantee limits.
Bharat Parenterals Business Update
Innoxel Lifesciences, a Bharat Parenterals subsidiary, began U.S. commercial supply of its first CMO product. This adds recurring manufacturing revenue to its existing licensing income.
Bharat Parenterals Preferential Issue
Bharat Parenterals filed a corrigendum to its EGM notice for a preferential issue exceeding ₹100 Crore. It adds a Crisil monitoring agency disclosure per BSE direction.